Leading leukemia experts: High leukemia treatment costs may be harming patients
The increasing cost of treatments for chronic myeloid leukemia (CML) in the United States has reached unsustainably high levels and may be leaving many patients under- or untreated because they cannot afford care, according ...
Cancer
Apr 25, 2013 |
not rated yet |
0
Advances in molecular testing offer new hope for lung cancer patients
The emergence of molecular diagnostic testing in lung cancer offers new hope for patients battling the number one cancer killer in the United States and abroad. Now, for the first time after a decade of biomarker testing ...
Cancer
Apr 03, 2013 |
not rated yet |
0
Scientists investigate potential markers for a response to sunitinib in patients with metastatic RCC
Markers such as CA9, CD31, CD34 and VEGFR1/2 in the primary tumours might serve as predictors of a good response to a sunitinib treatment in patients with metastatic clear cell renal cell carcinoma (ccRCC), according to a ...
Cancer
Mar 18, 2013 |
not rated yet |
0
Multi-tasking imatinib boosts radiotherapy for bladder tumours
Cancer drug imatinib (Glivec) could boost radiotherapy treatment to destroy bladder cancer that has spread to the bladder wall, reveals research published in Cancer Research.
Cancer
Mar 04, 2013 |
not rated yet |
0
Gleevec's latest approval is for pediatric cancer
(HealthDay)—The anti-cancer drug Gleevec (imatinib) has received new U.S. Food and Drug Administration approval to treat the most common type of pediatric cancer, affecting some 2,900 children each year, the agency said ...
Cancer
Jan 25, 2013 |
not rated yet |
0
Drug targets hard-to-reach leukemia stem cells responsible for relapses
Researchers at the University of California, San Diego School of Medicine have discovered that hard-to-reach, drug-resistant leukemia stem cells (LSCs) that overexpress multiple pro-survival protein forms ...
Cancer
Jan 17, 2013 |
3.7 / 5 (3) |
0
|
EGFR mutation not prognostic factor in non-small cell lung cancer
Recent studies have demonstrated that molecular-targeted agents, such as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), may prolong survival of selected patients based on tumor biomarkers. The presence ...
Cancer
Jan 15, 2013 |
not rated yet |
0
Patients with EGFR exon 20 insertions have poorer prognosis
Exon 20 insertions are the third most common family of epidermal growth factor receptor (EGFR) mutations found in non–small-cell lung cancer (NSCLC). Little is known about cancers harboring these mutations aside from their ...
Cancer
Jan 15, 2013 |
not rated yet |
0
Enzyme accelerates malignant stem cell cloning in chronic myeloid leukemia
An international team, headed by researchers at the University of California, San Diego School of Medicine, has identified a key enzyme in the reprogramming process that promotes malignant stem cell cloning ...
Cancer
Dec 24, 2012 |
5 / 5 (1) |
0
|
Options increase for CML patients failed by existing drugs
The U.S. Food and Drug Administration (FDA) this month expanded the options for patients with chronic myeloid leukemia and one form of acute lymphoblastic leukemia that carries the Philadelphia chromosome (Ph+ALL). It approved ...
Cancer
Dec 21, 2012 |
not rated yet |
0
Novel test identifies patients most likely to benefit from ALK inhibition therapy
Approximately one in 20 patients with non-small cell lung carcinoma (NSCLC) has chromosomal aberrations targeting the anaplastic lymphoma kinase (ALK) gene. This has considerable implications for treatment because these patients ...
Medical research
Dec 12, 2012 |
not rated yet |
0
|
Improved treatments for chronic myeloid leukaemia have dramatically increased survival
Survival for people diagnosed with Chronic Myeloid Leukaemia (CML) has risen by nearly half, with around 58 per cent of people surviving their disease for at least five years compared with only around 40 p ...
Cancer
Dec 12, 2012 |
not rated yet |
0
Drug combination acts against aggressive chronic lymphocytic leukemia
A two-prong approach combining ibrutinib and rituximab (Rituxin®) to treat aggressive chronic lymphocytic leukemia (CLL) produced profound responses with minor side effects in a Phase 2 clinical trial at the University of ...
Cancer
Dec 10, 2012 |
5 / 5 (2) |
0
Cabozantinib active in castration-resistant prostate cancer
(HealthDay)—The orally bioavailable tyrosine kinase inhibitor cabozantinib (XL184) has clinical activity in men with castration-resistant prostate cancer (CRPC), according to a study published online Nov. ...
Cancer
Dec 03, 2012 |
not rated yet |
0
Clinical trial delivers good results in leukemia patients
Huntsman Cancer Institute (HCI) researchers Michael Deininger, M.D., Ph.D., and Thomas O'Hare, Ph.D., were part of a team that found a potent oral drug, ponatinib, effective in patients who have developed resistance to standard ...
Cancer
Nov 30, 2012 |
not rated yet |
0
